A Trial of the ALK Grass Tablet in Subjects With Hayfever

A Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Trial Assessing the Efficacy and Safety of ALK Grass Tablet in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis

This trial is performed to assess the efficacy and safety of the ALK Grass tablet for treatment of grass pollen induced rhinoconjunctivitis (hayfever).

Eligibility Criteria:

• A history of grass pollen induced rhinoconjunctivitis
• Positive skin prick test to grass
• Positive specific IgE to grass